Evidence map›Paper›PMID 41721589›Full record

ArticleAdvanced healthcare materials2026

High-Throughput Generation of Tumor Spheroids via Droplet Microfluidics for siRNA-Loaded Nanomedicine Assessment.

Ling Liu, Guoying Wang, Yang Zhang, Bingyang Shi, Ming Li

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ling LiuSchool of Engineering, Macquarie University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-2353-9140
Guoying WangMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-7997-1026
Yang ZhangSchool of Mechanical and Manufacturing Engineering, The University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-3534-8133
Bingyang ShiSchool of Biomedical Engineering, The University of Technology Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-1043-3163
Ming LiSchool of Engineering, Macquarie University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-7450-6205

Funding

Australian Research Council DP200102269Australian Research Council DP240100795Cancer Institute NSW 2022/ECF1449Macquarie University scholarshipsNational Health and Medical Research Council GNT2017679
6 · The paper itself

Abstract

Tumor spheroids, the most widely used model of 3D cell culture, have emerged as a viable platform for assessing drug responses. However, high-throughput validation of novel drugs using tumor spheroids remains hindered by the challenges in generating large-scale, homogeneous, and functionally relevant spheroids. Here, a flow-focusing droplet microfluidic platform is developed for high-throughput generation of uniform tumor spheroids, producing over 50 000 droplets within 5 min, with each microdroplet serving as an individual bioreactor for spheroid formation. The initial size of the tumor spheroids is tuned based on cell concentration and water-to-oil flow rate ratio during microdroplet generation. After being released from the microdroplets, the 3D tumor spheroids continue growing, reaching diameters exceeding 300 µm. The growth and functional characteristics of the spheroids are examined both in a liquid environment and in a 3D collagen matrix. Moreover, these tumor spheroids enable assessment of the therapeutic efficacy of siRNA-based nanomedicine that demonstrates enhanced performance compared to free siRNA treatments. This platform offers a robust and scalable approach for evaluating novel nanomedicines, providing valuable insights into their therapeutic potential and underlying mechanisms of action.

Indexed as

MicrofluidicsNanomedicineRNA, Small InterferingSpheroids, CellularCell Line, TumorHigh-Throughput Screening AssaysHumansMicrofluidic Analytical TechniquesRNA, Small Interferingdroplet microfluidicshigh‐throughput generationnanomedicinetumor spheroids

Identifiers

PMID41721589
PMCPMC13175295

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.